New Delhi: The Subject Expert Committee (SEC) of the Drug Controller General of India (DCGI) has asked Bharat Biotech for additional data on its Covid-19 vaccine, Covaxin, for administering it to children in 2-12 age group, sources said.
This development comes after the SEC discussed recommendations for the restricted emergency of Covaxin in children aged between 2-12.
No recommendations have been made as of now, sources told ANI.
However, the SEC, after a meeting on Thursday, has recommended restricted emergency use of Biological E’s Covid-19 vaccine, Corbevax, in children aged 5-12, said sources. Now, the DCGI will be giving approval for its emergency use authorisation.
The Corbevax vaccine is currently being administered to children in the age group of 12-14.
The vaccination drive for children in the age group of 15-18 years commenced on January 3 this year. They are being administered Covaxin.
The drive later expanded on March 16 to include children aged between 12-14 years. They are being administered Corbevax.
Overall, India is currently administering two Covid-19 vaccines to children above 12 years.
